STK11 and non-small cell lung carcinoma: In LKB1-Deficient NSCLC organoids, the WEE1 kinase inhibitor AZD1775 alone and in combination with DNA agents has significant anticancer effects (Richer et al., 2017), thus providing a potential clinical application for AZD1775 in LKB1-Deficient NSCLC.